

ALECTINIB 224 cps 150 MG

1200 mg/die

1 RID


900 mg/die

2 RID

600 mg/die




Non-Small-Cell
Lung Cancer
ALK+

Prima linea




4

12/10/2017





Non-Small-Cell
Lung Cancer
ALK+

Linee successive dopo crizotinib



16/02/2017



Testa a testa vs Brigatinib

Non-Small-Cell
Lung Cancer
ALK+

Neoadiuvante

Candidate for surgical resection of lung cancer
 Single arm

INDICAZIONI

TRIAL REGISTRATIVI

ESMO-MCBS

su trial registrativo

EMA

AIFA

REAL WORLD EVIDENCE

ONGOING TRIALS



Referenze

- **TRIAL REGISTRATIVI**

- Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer." New England Journal of Medicine 377.9 (2017): 829-838
- Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer. Journal of Thoracic Oncology 12.10 (2017): 1552-1560.

- **ESMO-MCBS**

- [https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?mcbs_score_cards_form\[searchText\]=alectinib](https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?mcbs_score_cards_form[searchText]=alectinib)

- **EMA**

- <https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa>

- **AIFA**

- (GU Serie Generale n.176 del 31-07-2018)

- **REAL WORLD EVIDENCE**

- Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer." Journal of managed care & specialty pharmacy 28.3 (2022): 305-314.
- Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases." JTO Clinical and Research Reports 4.4 (2023): 100483.
- ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study." Targeted Oncology (2023): 1-13.
- First-line alectinib vs. Brigatinib in advanced NSCLC with ALK rearrangement: real-world data." Cancer Research and Treatment (2023).
- Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program." Oncotarget 13 (2022): 812.

- **ONGOING TRIALS**

- <https://clinicaltrials.gov/search?cond=NSCLC&intr=alectinib&viewType=Table>